Business Wire

Quectel Unveils LG580P GNSS, RTK, Multi-Constellation, Multi-Band Module for High-Precision Navigation Applications

10.3.2025 09:00:00 CET | Business Wire | Press Release

Share

Quectel Wireless Solutions, a global IoT solutions provider, today announces the launch of the LG580P, a multi-constellation, multi-band GNSS module designed for high-precision positioning. The module supports multi-band signals across L1, L2, L5, and L6, enabling real-time kinematic (RTK) positioning and integrating a dual antenna heading algorithm for enhanced accuracy and reliability. As designers and developers seek to build devices that combine high precision positioning with low power consumption, the LG580P is an ideal choice for applications such as intelligent robots and devices utilized in precision agriculture, ADAS and autonomous driving.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310190167/en/

Quectel unveils LG580P GNSS, RTK, multi-constellation, multi-band module for high-precision navigation applications (Photo: Business Wire)

The module features built-in professional-grade interference detection and elimination algorithms that mitigate multiple types of narrowband interference. This significantly improves signal reception, especially in complex electromagnetic environments. The LG580P also supports anti-jamming with a built-in professional-grade NIC anti-jamming unit and supplies integrity detection information which aids control decisions in automatic navigation scenarios.

“We’re delighted to unveil the LG580P to bring a new level of high precision, robust, low power positioning capability to the precise navigation application sector,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “The compact form factor, low power consumption and secure features accommodate diverse user needs for multiple bands and constellations. The LG580P also offers a robust solution for complex scenarios in which high precision positioning and headings are required.”

The LG580P is highly versatile, supporting numerous satellite bands and constellations. The module offers Global Navigation Satellite System (GNSS) support for 1,040 tracking channels, enabling concurrent reception of GPS, GLONASS, Galileo, BDS, QZSS and NavIC constellations. In addition, the LG580P supports multiple SBAS systems, including WASS, EGNOS, BDSBAS, MSAS, GAGAN and SDCM.

This ultra-compact module measures just 21.0mm x 16.0mm x 2.6mm and operates in the -40 °C to +85 °C, widening its applicability further. It is RoHS compliant and features interfaces including UART, SPI, I2C and CAN. From Q2 2025, the module will also support Precise Point Positioning (PPP), leveraging Galileo High Accuracy Service (HAS) on the E6 signal and BDS B2b, enabling high position accuracy without the need for additional correction networks.

Quectel also provides two external full-band GNSS antennas compatible with the LG580P: the YEGR001W8AH, an active GNSS antenna with multiple mounting options, and the YEGD006U1A, ensuring reliable and high-precision positioning.

Visitors to MWC Barcelona and Embedded World Munich can learn more about the LG580P and other Quectel products at the Quectel stand. At MWC Barcelona, Quectel will be at Stand 5A19, while at Embedded World, attendees can find the stand at Stand 3-318. To schedule a meeting, attendees are invited to book an appointment here.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,600 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250310190167/en/

Contacts

Media: media@quectel.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye